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REVIEW
Transcriptional Regulation of CD4+ T Cell Differentiation in
Experimentally Induced Arthritis and Rheumatoid Arthritis
Yuya Kondo, Masahiro Yokosawa, Shunta Kaneko, Kotona Furuyama, Seiji Segawa,
Hiroto Tsuboi, Isao Matsumoto, and Takayuki Sumida
Rheumatoid arthritis (RA) is an autoimmune dis-
order characterized by chronic inflammation of the joint
synovium and infiltration by activated inflammatory cells.
CD4+ T cells form a large proportion of the inflammatory
cells invading the synovial tissue, and are involved in the
RA pathologic process. In general, CD4+ T cells differenti-
ate into various T helper cell subsets and acquire the func-
tional properties to respond to specific pathogens, and
also mediate some autoimmune disorders such as RA.
Because the differentiation of T helper cell subsets is deter-
mined by the expression of specific transcription factors in
response to the cytokine environment, these transcription
factors are considered to have a role in the pathology of
RA. Treg cells control an excess of Tcell–mediated immune
response, and the transcription factor FoxP3 is critical for
the differentiation and function of Treg cells. Treg cell dys-
function can result in the development of systemic autoim-
munity. In this review, we summarize how the expression
of transcription factors modulates T helper cell immune
responses and the development of autoimmune diseases,
especially in RA. Understanding the role of transcription
factors in the pathogenesis of autoimmunity may lead to
novel therapeutic strategies to control the differentiation
and function of both T helper cells and Treg cells.
Introduction
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disorder characterized by autoimmunity, infiltration
of activated inflammatory cells into the joint synovium,
synovial hyperplasia, neoangiogenesis, and progressive
destruction of cartilage and bone. CD4+ Tcells constitute
a large proportion of the inflammatory cells invading the
synovial tissue. Upon antigenic stimulation and cytokine
signaling, naive CD4+ T cells activate and differentiate
into various T helper cell subsets.
Classically, interferon-c (IFNc)–producing Th1
cells had been considered to play a predominant role in
the development of RA. However, studies have demon-
strated that the Th1 phenotype does not explain all of the
mechanisms involved in RA (1).
The pathogenic role of interleukin-17 (IL-17)–pro-
ducing Th17 cells has intrigued rheumatologists, because
IL-17 is spontaneously produced by rheumatoid synovium
(2), and Th17 cells are increased among peripheral blood
mononuclear cells of RA patients compared with those of
healthy control subjects (3). Th17 cells also appear to play
a critical role in the generation of autoimmune arthritis in
several experimental models. In addition, some studies
have shown that the frequency of follicular helper T (Tfh)
cells, which support high-affinity and long-term antibody
response, is increased in the peripheral blood of RA
patients and correlates with disease activity (4), suggesting
that these cells also play a role in RA pathology. More
recently, it was reported that PD-1highCXCR5CD4+ T
cells were markedly expanded and activated in synovium,
and appeared to be poised to promote B cell response
and antibody production through expression of IL-21–like
Tfh cells within pathologically inflamed nonlymphoid tis-
sue in patients with RA (5).
Differentiation of naive CD4+ Tcells into T helper
cell subsets is dependent on the expression of specific
transcription factors induced by specific cytokines. Each
Supported by the Research Program for Intractable Diseases,
Health and Labor Sciences Research Grants from the Ministry of
Health, Labor and Welfare, Japan, and Grants-in Aid for Scientific
Research (Grant-in-Aid for Scientific Research [C]) from the Ministry
of Education, Culture, Sports, Science and Technology and Japan
Society for the Promotion of Science.
Yuya Kondo, MD, PhD, Masahiro Yokosawa, MD, PhD,
Shunta Kaneko, MD, Kotona Furuyama, Seiji Segawa, PhD, Hiroto
Tsuboi, MD, PhD, Isao Matsumoto, MD, PhD, Takayuki Sumida,
MD, PhD: University of Tsukuba, Tsukuba, Japan.
Address correspondence to Takayuki Sumida, MD, PhD,
Department of Internal Medicine, Faculty of Medicine, University of
Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. E-mail:
tsumida@md.tsukuba.ac.jp.
Submitted for publication July 14, 2017; accepted in revised
form December 5, 2017.
653
ARTHRITIS & RHEUMATOLOGY
Vol. 70, No. 5, May 2018, pp 653–661
DOI 10.1002/art.40398
© 2017 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc.
on behalf of American College of Rheumatology. This is an open access article under
the terms of the Creative Commons Attribution-NonCommercial License, which
permits use, distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
T helper cell–specific transcription factor not only regu-
lates the expression of effector molecules—e.g., cytokines
and chemokine receptors specific for each T helper cell
subset—but also negatively regulates the differentiation
of other Tcell subsets. Interestingly, CD4+ Tcells overex-
press RORC (encoding retinoic acid receptor–related
orphan nuclear receptor ct [RORct], a transcription fac-
tor), in RA patients but not in healthy subjects (3). Sev-
eral studies using animal models of RA have highlighted
T helper cell–specific transcription factors in the develop-
ment of autoimmune arthritis, and we have previously
described how the pathogenesis of murine autoimmune
arthritis is regulated by T-bet and RORct, which are
specific transcription factors in Th1 and Th17 cells,
respectively (6,7).
Treg cells control not only excess T cell–mediated
immune responses against pathogens, but also autoreac-
tive T cells, and thus they play a pivotal role in maintain-
ing peripheral self tolerance. Transcription factor FoxP3 is
needed to maintain the suppressive capacity of Treg cells
(8). Previous studies stressed the importance of FoxP3+
Treg cells in the regulation of autoimmune arthritis in
both human subjects and animal models, and our group
reported that the balance between FoxP3+ Treg cells and
Th17 cells in inflamed joints plays a critical role in the
severity of arthritis (7).
In this review, we summarize the latest research
findings on transcription factors in the differentiation,
function, and roles of CD4+ T cells in the development
of autoimmune arthritis. In particular, we focus on the
effects of T-bet and RORct expression in autoimmune
arthritis based on our previous findings in murine
autoimmune arthritis. Furthermore, we focus on tran-
scription factors as a potential target of new therapies
for autoimmune arthritis based on modulation of
CD4+ T cell differentiation.
Distinct role of CD4+ T cells in immune response
CD4+ T helper cells are divided into several subsets
based on their function, cytokine profile, and chemokine
receptor expression (Table 1). Th1 cells produce IFNc and
play an important role in immunity against intracellular
pathogens, whereas Th2 cells produce IL-4, IL-5, and IL-
13, and are essential for defense against parasites and
extracellular pathogens (9). Furthermore, Th17 cells pro-
duce IL-17, IL-21, and IL-22, and are involved in immu-
nity against bacterial and fungal infections (10–12). Tfh
cells are also a subset of CD4+ T cells and play a critical
role in humoral immune response. IL-21, produced by Tfh
cells, supports B cell proliferation and differentiation of
plasma cells in germinal centers (13,14). Localization of
T helper cells in inflammatory conditions depends mainly
on chemokines and their receptor expression. T helper cells
characteristically express specific chemokine receptors—
Th1, Th2, Th17 and Tfh cells express CXCR3, CCR4 and
CCR8, CCR6, and CXCR5, respectively—and migrate into
sites of inflammation in response to the chemokine ligands
(15). Thus, the expression patterns of chemokine receptors
are recognized as markers to standardize immunopheno-
typing of human T helper cells, and are used to isolate
viable T helper subpopulations (by cell sorting) to analyze
gene expression (16).
Treg cells suppress not only excess T cell-mediated
immune responses against pathogens, but also autoreac-
tive T cells. Thus, these cells play an important role in
maintaining peripheral self tolerance (17). Breakdown of
self tolerance contributes to the development of autoim-
mune diseases, such as antibody responses against citrulli-
nated self proteins in RA. Transcription factor FoxP3 is
required in order to maintain the suppressive properties of
CD4+CD25+ Treg cells (8). FoxP3+ Treg cells are divided
into thymus-derived Treg cells and Treg cells derived
peripherally. The former type is generated through the
recognition of self peptide and major histocompatibility
complex complexes in the thymus, and is thus important
for self tolerance (18). FoxP3+ Treg cells exert their
immunosuppressive functions through a variety of effector
mechanisms, such as up-regulation of CTLA-4 (19), con-
sumption of IL-2 (20), and production of immunosuppres-
sive cytokines, such as IL-10 (21) and transforming growth
factor b (TGFb) (22).
Table 1. Characteristics of T helper and Treg cells in normal immune response*
T cell
type Function
Cytokine
Chemokine
receptor ReferencesMajor Minor
Th1 Immunity against intracellular pathogens IFNc – CXCR3+CCR6 9, 15
Th2 Immunity against parasites and extracellular pathogens IL-4, IL-5, and IL-13 IL-10 CCR4+CCR8+ 9, 15
Th17 Immunity against bacterial and fungal infections IL-17 and IL-22 IL-21 CXCR3CCR6+ 10–12, 15
Tfh Humoral immune response by supporting B cell
proliferation and plasma cell differentiation
IL-21 IL-4 and IL-10 CXCR5+ 13–15
Treg Maintaining peripheral self-tolerance IL-10 and TGFb – – 8, 18–22
* IFNc = interferon-c; IL-4 = interleukin-4; Tfh = T follicular helper cell; TGFb = transforming growth factor b.
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Regulation of CD4+ T cell differentiation and function
by transcription factors
Differentiation of naive CD4+ Tcells into each type
of T helper cell subset depends on the expression of speci-
fic transcription factors induced by specific cytokines
(Table 2). For example, differentiation of naive CD4+ T
cells to Th1 cells depends on the expression of the tran-
scription factor T-bet, which is induced by T cell receptor
(TCR) stimulation, the IL-12/STAT-4 signaling pathway,
and the IFNc/STAT-1 signaling pathway (23–25). T-bet
directly activates the production of IFNc (23). On the other
hand, differentiation of Th2 cells is dependent on the
induction of transcription factor GATA-3 by the IL-4/
STAT-6 pathway (26,27). Similarly, Th17 cell differentiation
in mice is determined by the expression of transcription
factor RORct induced by TGFb and the IL-6/STAT3 path-
way (28–30). RORct is also up-regulated in human Th17
cells (31), and TGFb with IL-1b and IL-6, with IL-1b and
IL-21, or with IL-1b and IL-23 can induce RORct and
IL-17 expression in naive human CD4+ T cells (32,33).
Down-regulation of RORct inhibits Th17 cell differentia-
tion, suggesting that RORct is a master transcription factor
in Th17 cell differentiation. Other transcription factors
such as RUNX-1 and aryl hydrocarbon receptor (Ahr) are
also known to enhance Th17 differentiation dependent on
or independent of RORct (34–36). In Tfh cells, Bcl-6 has
been identified as the transcription factor involved in the
induction of differentiation (37,38). Furthermore, Bcl-3
was also recently reported to enhance the differentiation of
human Tfh cells (39).
Previous studies have demonstrated that these
transcription factors negatively regulate the differentia-
tion of other Tcell subsets by direct co-interaction and/or
an indirect effect of cytokine production by each T cell
subset. T-bet interacts directly with GATA-3, and inhibits
transcriptional activity (40). T-bet also inhibits the expres-
sion of RORct by interacting with RUNX-1, which
induces the expression of RORct and IL-17 (41), and the
indirect suppression of STAT-3 phosphorylation via the
IFNc/STAT-1/SOCS-3 pathway (42). Moreover, we
recently reported that T-bet regulates Th17 differentiation
through inhibition of Ahr expression (43).
The suppressive capacity of Treg cells requires the
presence of FoxP3. FoxP3+ Treg cells can also undergo
stimulus-specific differentiation, which is regulated by the
expression of transcription factors typically associated
with the differentiation of conventional CD4+ T helper
cells (44). These mechanisms affect the migratory and
functional features of effector Treg cells matched to the
environment that induced the initial response. Thus,
FoxP3+ Treg cells are phenotypically and functionally
diverse, and closely parallel the differentiation state of
conventional Tcells that occupy the same regulatory envi-
ronment and tissue niche.
Pivotal roles of T helper and Treg cells in
the pathogenesis of RA and experimentally
induced arthritis
The importance of CD4+ Tcells in the pathogenesis
of RA has been demonstrated in some studies, including
investigations on the infiltration of T cells in inflammatory
synovial tissue, the association of HLA genes with sus-
ceptibility to RA (45), and the effectiveness of CTLA-4
immunoglobulin Fc fusion protein and of abatacept in
RA (46). In particular, the HLA alleles associated with
susceptibility to RA are HLA–DR4 (DRB1*0401, *0404,
and *0405), HLA–DR1 (DRB1*0101 and *0102), and
HLA–DR10 (DRB1*0101), all of which share a con-
served 5-residue motif ([Q/R]-[R/K]-R-A-A) in their
peptide-binding groove, called the shared epitope (47).
Thus, susceptibility-associated HLA alleles are likely
to affect antigen presentation, especially in citrullinated
antigens (47).
The precise role of CD4+ T cell subpopulations
and their secreting cytokines in RA remains unclear. In
addition, it is uncertain how transcription factors regulate
Table 2. Association of T helper cells and their cytokines with RA*
T cell type/
cytokine Findings References
Th1/IFNc T cell clones from RA synovium produce large amounts of IFNc; IFNc inhibits bone resorption mediated by
suppression of osteoclast formation; monoclonal antibody to IFNc is less effective in RA
1, 48, 49
Th2/IL-4 SNPs in the coding region of IL-4R modulate the course and severity of RA via the magnitude of IL-17 production 53, 54
Th17/IL-17 IL-17 is spontaneously produced by the RA synovium; higher proportion of Th17 cells among peripheral blood
mononuclear cells in RA compared with healthy subjects; correlation with RA disease activity
2,3
Tfh/IL-21 High proportion of circulating Tfh-like cells in peripheral blood of RA patients; correlation with RA disease
activity; significantly high levels of serum IL-21 in RA
4, 71
Treg/– RA risk SNPs overlap with epigenetically activated H3K4me3 peaks in Treg cells 74
* RA = rheumatoid arthritis; SNPs = single -nucleotide polymorphisms; IL-4R = IL-4 receptor; H3K4me3 = histone H3 trimethyl lysine 4
(see Table 1 for other definitions).
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the differentiation and function of T helper cells and Treg
cells in RA. However, several new findings have been
revealed in studies of RA patients and of animal models
of autoimmune arthritis that focused on the functional
role of Th17 and Tfh cells in RA. Herein we summarize
the role of cytokine and transcription factor expression in
each T cell subpopulation in the pathology of human and
experimental RA.
Th1 cells. Classically, Th1 cells have been consid-
ered to play a predominant role in inflammatory RA,
because most synovium-infiltrating CD4+ T cells express
IFNc, and IFNc activates macrophages and induces pro-
duction of the proinflammatory cytokine tumor necrosis
factor (TNF) (1). However, a number of studies have
demonstrated that the Th1 phenotype does not explain all
of the mechanisms involved in RA, such as the inhibition
of bone resorption mediated by the suppression of osteo-
clast formation by IFNc (48), and the lack of efficacy of
monoclonal antibodies to IFNc in most patients (49)
(Table 2). In animal models of RA, IFNc also exhibits
antiinflammatory properties during the development of
autoimmune arthritis; the severity of collagen-induced
arthritis (CIA) is exacerbated in both IFNc-deficient mice
and IFNc receptor–deficient mice (50,51) (Table 3).
We previously reported significant suppression of
CIA in CD2-specific, T-bet transgenic mice, that were cul-
tured for Th17 cell differentiation (6). In the same study,
we also found that T-bet overexpression suppressed the
expression of RORct, resulting in inhibition of differenti-
ation of antigen-reactive Th17 cells, and that the regula-
tory effect was independent of IFNc (6). Another study
showed that T-bet deficiency did not affect the develop-
ment of arthritis in a transfer model of arthritogenic KRN
TCR transgenic T cells in TCR-deficient mice (52)
(Table 4). These data suggest the possibility that Th1 cells
induced by T-bet and their major cytokine IFNc might not
only facilitate the inflammation of RA but also have a
protective role in the pathology of RA.
Th2 cells. The Th1/Th2 paradigm, in which Th2
cells and their cytokines, such as IL-4 and IL-10, suppress
Th1 cells, had been used to understand the pathology of
RA. However, recent studies have focused on the rela-
tionships between Th2 cells and Th17 cells. A single-
nucleotide polymorphism (SNP) in the coding region of
IL-4R, governing the presence of isoleucine versus valine
at position 50 in the amino acid sequence, affects the
course and severity of RA (53) (Table 2). In addition, this
polymorphism in IL-4R controls the magnitude of IL-17
production (54) (Table 2). In animal models of RA, IL-4
also suppresses CIA disease activity (55) (Table 3).
Table 3. Association of T helper cells and their cytokines with
murine autoimmune arthritis models*
T cell type/cytokine,
experimental system Disease Phenotype Reference
Th1/IFNc
Deficiency CIA Exacerbation 50
Deficiency of IFNc
receptor
CIA Exacerbation 51
Th2/IL-4, treatment with
IL-4
CIA Amelioration 55
Th17/IL-17
Deficiency CIA Amelioration 57
Blocking antibody CIA Amelioration 58
Blocking antibody GIA Amelioration 59
Th17/IL-22, deficiency CIA Amelioration 61
Tfh/IL-2, blocking antibody CIA Amelioration 72
Treg/–
Depletion of CD25+ cells CIA Exacerbation 76
Transfer of CD4+CD25+
Treg cells
K/BxN
arthritis
Amelioration 77
* CIA = collagen-induced arthritis; GIA = glucose-6-phosphate isomerase–
induced arthritis (see Table 1 for other definitions).
Table 4. Association of genetic modulation of transcription factors in CD4+ T cells with murine autoimmune arthritis models*
T cell type/transcription factor,
experimental system Disease Phenotype Mechanism Reference
Th1/T-bet
Transgenic CIA Suppression Inhibition of Th17 cell differentiation 6
Deficiency KRN T cell transfer Not affected Knockout of T-bet expression did not
inhibit induction of arthritis
52
Th2/GATA-3, transgenic Antigen-induced arthritis Suppression Inhibition of Th17 cell differentiation 56
Th17/RORct, transgenic CIA Suppression Accumulation of RORct+CCR6+FoxP3+
Treg cells in inflamed joints
7
Th17/Ahr, conditional knockout
(CD4+ cells)
CIA Suppression Decrease in Th17 cells 63
Tfh/Bcl6, conditional knockout
(CD4+ cells)
KRN T cell transfer Suppression Reduction in anti-GPI IgG titer due to
loss of Tfh cell differentiation
73
Treg/FoxP3, scurfy mutation K/BxN arthritis Acceleration Earlier autoantibody production 79
* CIA = collagen-induced arthritis; RORct = retinoic acid receptor–related orphan nuclear receptor ct; Ahr = aryl hydrocarbon receptor; Tfh = T
follicular helper cell; anti-GPI = anti–glucose-6-phosphate isomerase.
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There are few reports concerning the commitment
of Th2 cell–specific transcription factors to RA and its
animal models. In mouse models of autoimmune arthritis,
GATA-3 expression protects against joint inflammation
and destruction by reducing the differentiation of Th17
cells (56) (Table 4). Accordingly, Th2 cells induced by
GATA-3 may regulate the pathology of RA via inhibition
of Th1 and Th17 cells.
Th17 cells. As described above, a number of stud-
ies have shown the importance of Th17 cells in RA and its
animal models. A large proportion of IL-1–positive CD4+
T cells (Th17 cells) are found among peripheral blood
mononuclear cells in RA patients compared with healthy
control subjects, and their proportion correlates with sys-
temic disease activity both at disease onset and during the
progression of RA (3) (Table 2). Similarly, IL-17–produc-
ing Th17 cells appear to play a critical role in the develop-
ment of various forms of experimental autoimmune
arthritis; IL-17–deficient mice are resistant to CIA (57),
and blockade of IL-17 ameliorates the severity of proteo-
glycan G1 domain–induced arthritis (58) and CIA (59)
(Table 3). Moreover, Th17 cells induce osteoclastogenesis
through the up-regulation of RANKL on their surface,
and of osteoblasts and synovial fibroblasts via IL-17 (60).
IL-17 also induces the production of inflammatory cyto-
kines—such as TNF and IL-6—from synovial fibroblasts
and macrophages and enhances the accumulation of
inflammatory cells. IL-22 is produced by Th17 cells, and
IL-22–deficient mice have also shown amelioration of
CIA severity via a reduction in germinal center formation
in the spleen, along with a decline in germinal center B
cells (61).
The expression levels of RORC in CD4+ T cells
are higher in RA patients than healthy subjects (3)
(Table 5). We have also demonstrated that overexpres-
sion of RORct in CD4+ T cells induces high expression
of CCR6 and facilitates the migration of CD4+ T cells
into inflamed joints of RA patients via CCL20, a CCR6-
specific chemokine ligand (Kaneko S, et al: unpublished
observations). In addition, Nguyen et al (62) suggested
that Ahr accelerates the differentiation of Th17 cells by
regulating the expression of microRNAs (miRs), such as
miR-212. In studies that examined the relationship
between Ahr and the pathology of autoimmune arthritis
in animal models, T cell–specific, Ahr-deficient mice
(Lck-Cre Ahrflox/flox mice) showed significant suppres-
sion of CIA through a decrease in Th17 cells and an
increase in Th1 cells in lymph nodes, suggesting that Ahr
regulates the Th1/Th17 balance during the development
of autoimmune arthritis (63) (Table 4). Collectively,
these findings indicate that the pathology of RA might
be strongly influenced by an imbalance of the differentia-
tion and function of Th1 and Th2/Th17 cells.
Based on these immunomodulatory effects in RA
and its animal models, IL-17 blockade has been consid-
ered as a therapeutic option for RA, and clinical trials
exploring this possibility have been conducted. While the
IL-17–blocking antibodies secukinumab and ixekizumab
and their receptor brodalumab are reported to be thera-
peutically effective in RA, their efficacy appears to be
inferior to that of preexisting biologics, such as anti-TNF
agents (64,65). These results probably reflect the differ-
ences in the pathogenesis of RA and experimentally
induced arthritis in laboratory animals, as well as the
heterogeneity in the etiology of RA.
Moreover, several low-molecular weight com-
pounds that target various transcription factors and sig-
naling molecules have been synthesized and their
therapeutic effects tested in autoimmune diseases. For
example, tofacitinib, a JAK inhibitor, has been used for
the treatment of RA, and its efficacy is reported to be
better than or equal to that of biologic disease-modifying
anti rheumatic drugs (66). The effectiveness of tofacitinib
is reported to be due, at least in part, to the inhibition of
Th1 and Th17 cells differentiation (67). Several synthetic
ligands that bind to and inhibit RORct (RORct antago-
nists) have also been developed recently (68), and their
therapeutic potential in autoimmunity has been assessed
in at least some animal models. In CIA, RORct antago-
nism ameliorated the severity of arthritis (69), and our
own data (70) confirmed that RORct antagonists can sup-
press autoimmune sialadenitis in mice with type 3
Table 5. Association of genetic modulation of transcription factors in CD4+ T cells with RA*
T cell type/transcription
factor Findings Reference
Th17/RORC RORC overexpression in CD4+ T cells of RA patients 3
Th17/Ahr Ahr accelerates differentiation of Th17 cells 62
Tfh/ Bcl3 Significantly high Bcl-3 levels in RA patients; Bcl-3 up-regulates Bcl-6 expression and induces
IL-21–producing CD4+ T cells
39
Treg/FoxP3 In RA patients, FoxP3+ Treg cells lose their suppressive capacity by inhibition of transcriptional
activity of FoxP3 through dephosphorylation by TNF
78
* RA = rheumatoid arthritis; Ahr = aryl hydrocarbon receptor; TNF = tumor necrosis factor (see Table 1 for other definitions).
ROLE OF TRANSCRIPTION FACTORS IN PATHOLOGY OF RA 657
muscarinic acetylcholine receptor–induced sialadenitis.
These findings add support to the concept that auto-
immunity, especially in RA, can potentially be treated
by targeting one or more transcription factors.
Tfh cell and PD-1highCXCR5 activated T cells.
Some studies have shown that Tfh cells also play an impor-
tant pathogenic role in RA; a high proportion of circulating
CXCR5+PD-1+CD4+ Tfh–like cells is found in patients
with RA, and correlates positively with RA disease activity.
Furthermore, serum IL-21 levels are significantly increased
in RA patients and correlate with RA disease activity (4,71)
(Table 2). Recent studies have also demonstrated the impor-
tant role of Tfh cells in the pathology of autoimmune arthri-
tis; blockade of IL-21 suppresses the development of CIA
(72) (Table 3).
Meguro et al have reported that levels of tran-
scription factor Bcl-3 were significantly higher in RA
patients compared with healthy subjects and that Bcl-3
up-regulates the expression of Bcl-6—a master transcrip-
tion factor of Tfh cells—and induces IL-21–producing
CD4+ Tcells (39) (Table 5). In a model using transfer of
arthritogenic KRN TCR– transgenic T cells into TCR-
deficient mice, conditional deletion of Bcl-6 in T cells
(CD4-Cre Bcl-6flox/flox mice) blocked Tfh differentiation,
resulting in inhibition of arthritis through a reduction in
autoantibody formation. In contrast, conditional deletion
of IL-17 in T cells (CD4-Cre IL-17aflox/flox mice) had no
effect on the development of arthritis in the same model
(73) (Table 4). These findings suggest that autoantibody
formation in autoimmune arthritis is regulated mainly by
Bcl-6–induced Tfh cells rather than by Th17 cells.
Recently, using mass cytometry, Rao et al identi-
fied PD-1highCXCR5– T cells among activated T cells
infiltrating RA synovium (5). Like Tfh cells, PD-1high
CXCR5– activated T cells expressed some factors
enabling B cell help, including IL-21 and CXCL13, and
induced plasma cell differentiation in vitro. In addition,
PD-1highCXCR5– T cells may infiltrate chronically
inflamed tissues, recruit both Tfh cells and B cells, and
promote local autoantibody formation in ectopic lym-
phoid structure. The expression of transcription factor
Bcl-6 is not elevated in PD-1highCXCR5– Tcells, while B
lymphocyte–induced maturation protein 1, a transcription
factor typically down-regulated in Tfh cells, is up-regu-
lated. Thus, the transcriptional regulation of the differen-
tiation of PD-1highCXCR5– Tcells was different from that
of Tfh cells, although both cell types are related in
autoantibody formation in RA (5).
Taken together, the above findings demonstrate
that not only Tfh cells, but also PD-1highCXCR5– Tcells,
have a central role in the pathology of RA via facilitation
of B cell help to produce autoantibodies. The precise reg-
ulatory mechanism of these cells’ differentiation, how-
ever, remains to be clarified.
Treg cells. A meta-analysis of genome-wide associ-
ation in RA patients that evaluated ~10 million SNPs
revealed that biologic RA risk genes segregate in a region
where RA risk and SNP overlap with epigenetically acti-
vated H3K4 trimethylation peaks in Treg cells (74)
(Table 2). These findings highlight the important role of
Treg cells in the pathogenic process of RA, though the
exact regulatory mechanisms of these cells also remain
Figure 1. Regulation of transcription factors involved in the pathogenesis of experimentally induced autoimmune arthritis. The potential relationships
among various transcription factors involved in the pathology of rheumatoid arthritis (left) and experimentally induced autoimmune arthritis (right) are
shown. APC = antigen-presenting cell; IL-6R = interleukin-6 receptor; RORct = retinoic acid receptor–related orphan nuclear receptor ct; IFNcR =
interferon-c receptor; SOCS3 = suppressor of cytokine signaling 3; Ahr = aryl hydrocarbon receptor.
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elusive. While previous studies of the role of the Treg cell
population in RA differed in their estimation of the pro-
portion of circulating Treg cells, they consistently showed
the presence of high numbers of these cells in the
inflamed joints of RA patients (75). Treg cells appear to
have regulatory roles in the development of murine
autoimmune arthritis, because depletion of CD25+ cells
exacerbates CIA (76), and transfer of CD4+ CD25+ Treg
cells ameliorates the development of arthritis (77)
(Table 3).
With regard to FoxP3 specifically, it is reported
that FoxP3+ Treg cells in RA patients lose their suppres-
sive capacity by inhibiting the transcriptional activity of
FoxP3 through dephosphorylation by TNF (78) (Table 5).
FoxP3-deficient KBx/N mice, which spontaneously de-
velop autoimmune arthritis, have shown faster and more
aggressive disease (79) (Table 4). In our studies of CIA in
CD2-specific RORct transgenic mice, the majority of
FoxP3+ Treg cells highly expressed RORct and CCR6,
and accumulated in the inflamed joints. Moreover, Treg
cells produced high amounts of IL-10, but not IL-17,
resulting in the attenuation of severity of CIA compared
with disease in wild-type mice (7) (Table 4). On the other
hand, it has also been reported that CD25lowFoxP3+
T cells lose FoxP3 expression and redifferentiate into
arthritogenic Th17 cells (exFoxP3 Th17 cells) (80).
These results suggest that the suppressive function
of FoxP3+ Treg cells may be impaired by the inflamma-
tory conditions of RA. Future research is needed to
understand the mechanisms that regulate a balance be-
tween T helper cells and Treg cells in RA.
Conclusions
In this review, we have summarized the latest re-
search findings concerning the roles of transcription fac-
tors in the differentiation and function of CD4+ Tcells in
autoimmune arthritis. There is no doubt that the propor-
tions and functional imbalances among various T helper
cell subsets and between T helper and Treg cells play a
critical role in RA pathogenesis. There is a need for more
research into the role of transcription factors in human T
helper cell differentiation: specifically, how the different
transcription factors regulate arthritogenic T helper cells
and the development of RA (Figure 1). Previous studies
in mice have shown convincing evidence of the importance
of transcription factors in the differentiation and function
of both T helper and Treg cells. In addition, the available
data confirm the role of transcription factors in the devel-
opment of murine autoimmune arthritis through the regu-
lation of differentiation of arthritogenic Th17 cells
(Figure 1). Although more work is needed to determine
how the expression of transcription factors in CD4+ Tcells
regulates the balance between T helper and Treg cells,
especially in RA patients, we believe that new approaches
that target specific transcription factors, and hence modu-
lation of differentiation and function of CD4+ T cells,
could likely yield efficacious therapies for RA.
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